Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, and Patient Eligibility

By João L. Carapinha

April 8, 2025

The German Federal Joint Committee (G-BA) has approved a new indication for Pembrolizumab Enfortumab therapy in combination with Enfortumab Vedotin as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. This decision is based on a structured benefit assessment comparing this therapy to standard treatments. It focuses on patients’ eligibility for cisplatin-based regimens. For those ineligible for either cisplatin or carboplatin, no additional benefit was found.

Clinical Effectiveness Overview

  • Mortality Benefits: In cisplatin-eligible patients, the combination therapy showed a mortality benefit but lacked quantifiable superiority over cisplatin/gemcitabine. For carboplatin-eligible patients, it demonstrated significant mortality improvement compared to carboplatin/gemcitabine, along with symptomatic benefits like reduced nausea and constipation. However, for patients ineligible for both, no efficacy was shown over alternatives like Atezolizumab monotherapy or best supportive care.

Economic Aspects

  • Cost Implications: The annual treatment costs for Pembrolizumab Enfortumab therapy are much higher than standard therapies, estimated at €181,464 per patient. Standard options include carboplatin, and gemcitabine, or maintenance therapy with avelumab, depending on the regimen and patient subgroup.

Safety Profile and Adverse Events

  • Benefits and Risks: The combination therapy has advantages, such as fewer severe adverse effects, and risks, including immune-related side effects like severe hyperglycemia.

Regulatory and Assessment Framework

The G-BA conducts early benefit assessments under the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG). This process compares new therapies against existing standards to ensure efficient resource use in Germany’s statutory health insurance (GKV) system. Pembrolizumab is a PD-1 checkpoint inhibitor, while Enfortumab Vedotin is an antibody-drug conjugate targeting Nectin-4.

Implications for Healthcare Economics and Access

  1. Healthcare Economics: The high cost of Pembrolizumab Enfortumab therapy raises affordability concerns. Its benefits for some subpopulations may limit widespread use.
  2. Reimbursement Challenges: High costs and limited evidence for certain groups may hinder reimbursement. Price negotiations with GKV payers could lead to reductions.
  3. Addressing Unmet Needs: The lack of benefits for cisplatin- and carboplatin-ineligible patients highlights the need for alternative treatments. More research could improve outcomes.

Final Reflections

The G-BA’s decision reflects a tailored approach to clinical effectiveness. While Pembrolizumab Enfortumab therapy shows promise for select groups, its high costs and selective effectiveness emphasize the need for precision medicine and cost containment. For details, see the G-BA’s official assessment.

Reference url

Recent Posts

Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy
Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC

By João L. Carapinha

October 20, 2025

If you're searching for effective options in Keytruda lung cancer treatment, recent data shows pembrolizumab (Keytruda) significantly boosts survival rates in non-small cell lung cancer (NSCLC). In the KEYNOTE-671 trial, this immunotherapy combined with chemotherapy raised five-year overall survi...